Medical Mycology: Diagnosis, Management, and Prevention of Fungal Diseases

Medical Mycology

Diagnosis, Management, and Prevention of Fungal Diseases

Fungal diseases, or mycoses, are among the most challenging infections to diagnose and treat due to their subtle clinical signs and resistance to antimicrobial agents. Understanding the epidemiology, clinical manifestations, diagnosis, and treatment options is essential for effective management.

• Mycoses often present with signs that are missed or misinterpreted.

• Fungi are frequently resistant to antimicrobial agents.

Epidemiology of Mycoses

Distribution and Transmission

Fungi and their spores are ubiquitous in the environment, and most individuals will experience a mycosis during their lifetime. Transmission typically occurs via inhalation, trauma, or ingestion, but most mycoses are not contagious, with dermatophytes as a notable exception.

• Fungi are present almost everywhere.

• Mycoses are usually acquired from environmental sources.

• Person-to-person transmission is rare, except for dermatophytes.

• Epidemics can occur due to mass exposure.

• Mycoses are not reportable diseases, so data on their occurrence is limited.

Categories of Fungal Agents

True Pathogens vs. Opportunistic Fungi

Fungal agents are classified as either true pathogens or opportunistic fungi. Only four fungi are considered true pathogens, while others cause disease primarily in immunocompromised individuals.

• True fungal pathogens: Cause disease in healthy hosts.

• Opportunistic fungi: Cause disease in hosts with compromised immunity or disrupted microbiome.

Factors Predisposing to Opportunistic Mycoses

Several factors increase the risk for opportunistic mycoses, including medical procedures, therapies, disease conditions, and lifestyle factors.

Factor	Examples
Medical procedures	Surgery, medical implants, catheterization
Medical therapies	Immunosuppressive therapy, cancer treatments, steroids, long-term antibiotics
Disease conditions	Immune defects, leukemia, AIDS, diabetes, burns, chronic illnesses
Lifestyle factors	Malnutrition, poor hygiene, IV drug abuse

Clinical Manifestations of Fungal Diseases

Types of Fungal Diseases

• Fungal Infections: Most common, caused by true pathogens or opportunists.

• Fungal Toxicities: Acquired through ingestion of poisonous mushrooms.

• Allergies: Result from inhalation of fungal spores.

Diagnosis of Fungal Infections

Diagnostic Methods

Patient history is critical, but definitive diagnosis often requires morphological analysis of the fungus. Sabouraud Dextrose Agar is commonly used to culture fungi, favoring their growth.

• Distinguishing infection from exposure is challenging.

• Opportunistic infections are especially difficult to diagnose.

Antifungal Therapies

Challenges and Treatments

Mycoses are difficult to treat due to similarities between fungal and human cells. Ergosterol is a common target for antifungal drugs, but these drugs can harm human tissues.

• Amphotericin B: Gold standard, but highly toxic.

• Opportunistic infections require high-dose initial treatment followed by low-dose maintenance.

Antifungal Vaccines

Vaccines against fungal infections are difficult to develop and are not routinely administered. Most fungal infections occur in immunosuppressed patients, and vaccine efficacy in humans remains uncertain.

• Vaccines have been developed for mice against Candida, Aspergillus, and Cryptococcus.

• Human efficacy is unknown.

Systemic Mycoses

Pathogenic Fungi of Ascomycota

Systemic mycoses are caused by four pathogenic fungi of the division Ascomycota: Histoplasma, Blastomyces, Coccidioides, and Paracoccidioides. These infections are acquired by inhalation and begin as pulmonary infections before disseminating via the bloodstream.

• All four are dimorphic: mycelial thalli in environment, yeast in body.

• Precautions are necessary when working with these fungi due to invasive forms.

Histoplasmosis

Histoplasma capsulatum is the most common fungal pathogen affecting humans, found in moist soils with high nitrogen. Most infections are asymptomatic, but can result in chronic pulmonary, cutaneous, systemic, or ocular histoplasmosis.

• Diagnosis: Identification of yeast in patient samples.

• Treatment: Amphotericin B or ketoconazole.

Blastomycosis

Blastomyces species are found in soils rich in organic matter and can cause pulmonary, cutaneous, osteoarticular, or meningitis forms.

• Pulmonary blastomycosis: Most common, often asymptomatic.

• Cutaneous: Painless lesions on face and upper body.

• Osteoarticular: Spread to bones and joints.

• Meningitis: CNS involvement, especially in AIDS patients.

• Treatment: Oral itraconazole or amphotericin B.

Opportunistic Mycoses

General Features

Opportunistic mycoses typically affect individuals with poor immunity or disrupted microbiome. They are increasingly important due to the rise in AIDS cases and are difficult to identify due to atypical symptoms.

Pneumocystitis Pneumonia

Pneumocystis jiroveci is an obligate parasite, commonly acquired by inhalation. It is a frequent opportunistic infection in AIDS patients and is almost diagnostic of AIDS.

• Treatment: Trimethoprim and sulfamethoxazole.

Candidiasis

Candida infections are transmitted between individuals, mostly affecting immunocompromised patients. Clinical manifestations vary by site and predisposing factors.

Type	Clinical Signs and Symptoms	Predisposing Factors
Oropharyngeal (thrush)	White plaques on mouth, tongue, gums, palate, pharynx	Diabetes, AIDS, cancer, chemotherapy
Cutaneous	Red rash between skin folds, diaper rash, onychomycosis	Moisture, heat, obesity, immunocompromised
Vulvovaginal	Creamy discharge, burning, redness, painful intercourse	Antibiotics, pregnancy, diabetes
Chronic mucocutaneous	Lesions on skin, nails, mucous membranes	Impaired immunity, diabetes
Neonatal/congenital	Meningitis, renal disorders, generalized rash	Young age, low birth weight, maternal antibiotics
Esophageal	White plaques, burning pain, nausea, vomiting	AIDS, immunocompromised
Gastrointestinal	Ulceration of stomach and intestines	Hematological cancers
Pulmonary	Nonspecific symptoms, often undiagnosed	Spread from other candidiasis
Peritoneal	Fever, pain, tenderness	Catheters, GI perforation
Urinary tract	Painful urination, discharge	Diaper rash, catheters, diabetes
Renal	Fever, pain, fungus ball	Blank
Meningeal	Swelling, fever, headache, neck stiffness	Spread during systemic infection
Hepatic/splenic	Fever, liver/spleen swelling, dysfunction	Leukemia
Endocardial/myocardial/pericardial	Fever, murmur, heart failure, anemia	Heart valve disease, catheters, IV drug abuse
Ocular	Cloudy vision, eye lesions	Spread, catheters, IV drug abuse, trauma
Osteoarticular	Pain on joint weight	Spread, prosthetic implants
Candidemia	Resistant fevers, tachycardia, hypotension, skin lesions	Catheters, antibiotics, surgery, burns

Aspergillosis

Aspergillus species are widespread and cause disease primarily through inhalation of spores. Allergies are most common, but pulmonary, cutaneous, and systemic forms can occur.

• Hypersensitivity: Asthma/allergies.

• Non-invasive: Fungal masses in lung cavities.

• Acute invasive: Pneumonia.

• Treatment: Allergy medications, surgical removal, intravenous voriconazole, maintenance with itraconazole.

Cryptococcosis

Cryptococcus neoformans and C. gattii infect immunocompetent and immunocompromised individuals, respectively. Infection occurs via inhalation of spores or dried yeast in bird droppings.

• Resists phagocytosis, prefers CNS.

• Clinical forms: Pulmonary, meningitis, cryptococcoma, cutaneous.

• Treatment: Amphotericin B and 5-fluorocytosine, maintenance with fluconazole.

Emergence of Fungal Opportunists in AIDS Patients

AIDS patients are highly susceptible to opportunistic fungal infections, which account for most AIDS-related deaths. Use of antifungal drugs can select for resistant fungi.

• Fusarium species: Respiratory distress, disseminated infections, fungemia, toxin accumulation.

• Talaromyces marneffei: Pulmonary disease.

• Trichosporon beigelii: Fatal systemic disease, entry via lungs, GI, or catheters.

Superficial, Cutaneous, and Subcutaneous Mycoses

General Features

These are the most commonly reported fungal diseases, usually localized at or near the surface of the body. They are acquired by person-to-person contact or environmental exposure and are rarely life-threatening.

Superficial Mycoses

Confined to the outer dead layers of skin, nails, and hair, which contain keratin. Dermatophytoses (ringworm) are infections of skin, nails, or hair caused by fungi that use keratin as a nutrient source.

• Can trigger immune responses that damage living tissues.

• Spread person-to-person or from contaminated soil/animals.

Common Dermatophytoses

Disease	Agents	Common Signs	Source
Tinea pedis (athlete's foot)	Trichophyton rubrum, T. mentagrophytes var. interdigitale, Epidermophyton floccosum	Red, raised lesions on toes/soles; webbing heavily infected	Human reservoirs, carpeting
Tinea cruris (jock itch)	T. rubrum, T. mentagrophytes var. interdigitale, E. floccosum	Red, raised lesions on groin/buttocks	Usually spreads from feet
Tinea unguium (onychomycosis)	T. rubrum, T. mentagrophytes var. interdigitale	Patches/pits on nail, yellowing/thickening, loss of nail	Humans
Tinea corporis	T. rubrum, Microsporum gypseum, M. canis	Red, ringlike lesions on skin surfaces	Spread from other sites, contaminated soil/animals
Tinea capitis	M. canis, M. gypseum, T. equinum, T. verrucosum, T. tonsurans, T. violaceum, T. schoenleinii	Arthroconidia outside/inside hair shaft, crusts, hair loss	Humans, contaminated soil/animals

Treatment: Limited infections with topical antifungal agents; widespread infections with oral antifungal agents.

Superficial: Malassezia Infections

Malassezia is a normal skin microbiome member causing pityriasis (depigmented/hyperpigmented patches of scaly skin). Diagnosis is based on budding yeast and short hyphal forms in samples.

• Superficial infections: Topical antifungal agents.

• Extensive infections: Oral therapy.

• Relapses are common.

Cutaneous & Subcutaneous Mycoses

These fungi are commonly found in soil and require traumatic introduction beneath the skin. They are less common than superficial mycoses.

• Chromoblastomycosis: Progressive skin lesions.

• Phaeohyphomycosis: Colonization of nasal passages/sinuses, especially in allergy sufferers and AIDS patients.

• Distinguished by morphology of fungal cells in tissue samples.

• Both are difficult to treat.

Sporotrichosis

Subcutaneous infection usually limited to arms and legs, acquired from soil or plant material. Produces nodular lesions and may enter lymphatic system.

• Diagnosis: Patient history, clinical signs, observation of dimorphic fungi in culture.

• Treatment: Topical agents.

• Prevention: Proper clothing when working with plants.

Fungal Intoxications and Allergies

Mycotoxicosis and Mycetismus

Some fungi produce mycotoxins or cause allergies. Mycotoxicosis is caused by eating mycotoxins, while mycetismus is mushroom poisoning from eating a fungus.

• Aflatoxins: Fatal, carcinogenic, cause liver damage/cancer, prevalent in tropics.

• Some mycotoxins (e.g., ergot alkaloids from Claviceps purpurea) are used in drug production.

Mycetismus

Most mushrooms are not toxic, but some produce dangerous mycotoxins causing neurological dysfunction, hallucinations, organ damage, or death.

• Gyromitra esculenta: Diarrhea, convulsions, death.

• Cortinarius gentilis: Thirst, nausea, kidney failure.

• Psilocybe cubensis: Psilocybin (hallucinogenic).

• Amanita muscaria: Ibotenic acid, muscimol (hallucinogenic).

• Death caps: Deadliest mushrooms, inhibit RNA synthesis, cause liver damage.

Treatment: Induced vomiting, activated charcoal, liver transplant in severe cases.

Allergies to Fungi

Fungal allergens are common indoors and outdoors, causing hypersensitivity reactions such as asthma, eczema, and hay fever. Type I hypersensitivity is most common; Type III is less frequent.

• Diagnosis is difficult due to environmental ubiquity of fungi.

Additional info: Fungal diseases are increasingly important in clinical practice due to rising numbers of immunocompromised patients. Early diagnosis and appropriate antifungal therapy are critical for successful outcomes.